101 Seaport Boulevard, 7th Floor
About Orchard Therapeutics
Orchard Therapeutics is a leading global fully integrated commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies.
Orchard’s portfolio of ex vivo autologous gene therapy programs has demonstrated sustained clinical benefit in over 150 patients across five disease areas. These programs include Strimvelis®, the first ex vivo autologous gene therapy approved by the EMA in 2016, three advanced registrational studies for metachromatic leukodystrophy (MLD), ADA-SCID and Wiskott-Aldrich syndrome (WAS), clinical programs for X-linked chronic granulomatous disease (X-CGD), transfusion-dependent beta-thalassemia (TDT) and mucopolysaccharidosis type I (MPS-I), as well as an extensive preclinical pipeline.
The company is partnered with world-leading institutions in gene therapy, including University College London, Great Ormond Street Hospital, the University of Manchester and Central Manchester University Hospitals, the University of California Los Angeles and Boston Children’s Hospital, and Telethon Institute of Gene Therapy/Ospedale San Raffaele.
Orchard is a publicly traded company (NASDAQ: ORTX) with offices in the UK and the US, including London and Boston.
98 articles with Orchard Therapeutics
A summary of IPOs from companies in the biotech and pharma world since Oct. 1, 2018.
Orchard Therapeutics plc (Nasdaq: ORTX), today announced the pricing of its initial public offering in the United States of 14,285,715 American Depositary Shares (“ADSs”) representing 14,285,715 ordinary shares at an initial public offering price of $14.00 per ADS, before underwriting discounts and commissions.
10/31/2018October was a busy month as multiple biopharma companies made their debut as publicly traded entities and even more companies filed their intentions to go public with an initial public offering. BioSpace takes a look back at some of the key IPOs of the month.
Orchard Therapeutics, with locations in Boston and London, UK, received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for OTL-300, a lentiviral gene therapy for transfusion-dependent beta-thalassemia (TDBT).
Orchard Therapeutics Receives EMA PRIME Designation for OTL-300, an Investigational Lentiviral Gene Therapy for the Treatment of Transfusion-Dependent Beta-Thalassemia
Orchard Therapeutics today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to OTL-300, an investigational autologous ex vivo lentiviral gene therapy for the treatment of transfusion-dependent beta-thalassemia (TDBT), the most severe form of beta-thalassemia.
9/4/2018Biopharm companies closed out August with a plethora of changes to executive and senior leadership positions. Let's take a look.
Orchard Therapeutics Expands Leadership Team with Appointments of Head of Corporate Communications and Head of Human Resources
Orchard Therapeutics, a leading commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies, today announced two additions to its executive leadership team.
Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today notes that the European Commission (EC) has approved the Novartis CAR-T cell therapy, Kymriah® (tisagenlecleucel, formerly CTL019).
It’s not easy to predict trends in drugs, especially with breakthroughs in immunology and genetic engineering often causing dramatic changes in how biopharma companies approach new drugs.
Four months after acquiring GlaxoSmithKline’s rare disease gene therapy portfolio, U.K.-based Orchard Therapeutics secured $150 million in an oversubscribed Series C funding round. The funds will be used to advance three late-stage programs that it gained from the deal with GSK.
Orchard Therapeutics, a leading commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies, today announced the completion of an oversubscribed $150 million Series C financing.
Orchard Therapeutics, a leading commercial-stage biotech company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies, today announced the appointment of Jon Ellis, Ph.D. as GSK’s designated representative to its board of directors.
7/16/2018With the Independence Day holiday in the rearview mirror, numerous biopharma companies continued to adjust their leadership ranks and strengthen the members of various boards representing and overseeing the companies.
Orchard Therapeutics, today announced the appointment of Joanne Beck, Ph.D., to its board of directors.
So far during the first six months of the year, more than $100 billion has been spent on a myriad of acquisitions across the pharma and biotech industries.
With the end of June, numerous biotechs shored up their boards of directors and other advisory boards with new members as the companies continued to shape their future strategies.
A new report highlights some concerns about the long-term commercial viability of game-changing gene therapies that can radically transform the lives of patients.
Biotech and pharmaceutical companies across the U.S. and globally shook up their senior leadership roles in the first week of June with new hires that included chief executive officers and directors.
Orchard Therapeutics Announces Appointments of Marc Dunoyer and Charlie Rowland to Board of Directors
Orchard Therapeutics today announced the appointments of Marc Dunoyer and Charlie Rowland to its board of directors as independent directors.
Imara Inc. today announced additions to its clinical development team with the appointments of Joe Datt, M.D., as Senior Vice President, Clinical Development, and Siddharth Parulkar as Head, Global Clinical Operations.